CW December 2004
Volume 13Issue Number 12 December 2004 ISSN 10593802 Atrasentan for Hormone-Refractory ProstateAbbott submits New Drug Application to the US Food and Drug Administration for the approval of atrasentan, a non-hormone, and non-chemotherapeutic agent to treat advanced hormone-refractory prostate cancer.
Go to Previous Page Go to Next Page Purchase Downloadable Full-text PDF of Article: $10.00 Subscription is more cost effective than purchasing PDFs on-the-fly. Click here for details. Download Complete Issue CW December 2004Purchase Downloadable Full-text PDF of Complete Issue: $20.00 |
|
Member Login | Home | Offices | Subscribe | Glossary | Cancer Technologies | Contact Us
Adenine Press, 2066 Central Avenue, Schenectady, NY 12304 USA |
Re-initialize IP-based Login |
